melanoma Archive — Page 1 of 3
-
July 1, 2021
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients. -
March 25, 2021
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology. -
December 17, 2020
Study reveals new strategy for reducing tumor growth, metastasis
A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma. -
April 23, 2020
Study explores melanoma drug’s effectiveness
A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma. -
August 15, 2019
Potential second-line melanoma treatment identified
A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients. -
March 28, 2019
Hot chemotherapy surgery helps save patient’s leg
Tom Deweese can keep up with his grandchildren because of a highly specialized surgery using hot chemotherapy that saved his leg. -
April 12, 2018
Entertainers’ support strengthens VICC melanoma research efforts
Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.